Discussion
Giant prolactinomas generally are defined by a diameter >4 cm, and they represent <5% of pituitary lesions [1] . While prolactinomas overall are diagnosed most frequently in reproductive-aged females, giant prolactinomas are diagnosed predominantly in middle-aged males.
Clinical history
In December 2007, a 44-year-old male living in the Middle East was diagnosed with meningitis. At that time, CT identified a nasopharyngeal mass (7.5 × 4.5 cm) involving the clivus and extending to the suprasellar region. Biopsy reportedly was consistent with nasopharyngeal carcinoma. He underwent five cycles of cisplatin and 5-fluorouracil. Subsequent MRIs in June and September 2008 showed an unchanged mass. He then relocated to the United States.
In October 2008, he presented upon referral to the University of Virginia Pituitary Clinic, where he reported low libido and daily frontotemporal headache. He denied galactorrhea and had no evidence of hypogonadism, Cushing's, or acromegaly.
Our initial imaging in September 2008 ( Fig. 1 ) showed a mass (3.7 × 3.1 × 5.5 cm) centered within the sella, clivus, and sphenoid sinus, invading the cavernous sinuses, elevating the optic chiasm, and extending into the nasopharynx. His baseline morning pituitary evaluation showed prolactin >164,000 ng/mL (<20), cortisol 8.7 μg/dL, total testosterone 173 pg/mL (310-1010), SHBG 29 nmol/L (13-71), free testosterone 35.1 pg/mL (47-244), LH 4.0 mIU/mL, FSH 11.5 mIU/mL, free T4 1.1 ng/dL (0.7-1.5), TSH 0.71 mIU/L (0.45-4.5), and IGF-1 87 ng/mL (87-267). Macroprolactin was not detected.
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Several aspects of this case are of interest. Despite the marked elevation of prolactin, gonadotropin levels were not suppressed. Considering that hyperprolactinemia should suppress GnRH secretion, this may reflect impaired bioactivity of the tumor prolactin. Alternatively, his prior chemotherapy may have resulted in testicular damage, leading to gonadotropin elevation due to inadequate sex steroid negative feedback. Additionally, while pituitary function initially was preserved, transient partial hypopituitarism occurred within a month of initiating cabergoline, with subsequent spontaneous recovery-although 5 years passed before restoration of hypothalamic-pituitary-gonadal function.
We hypothesize that the transient hormonal deficiencies could reflect compression and/or too-rapid elongation of the pituitary stalk during the initial tumor shrinkage, temporarily impairing stalk blood flow before subsequent recovery.
While replacement of cortisol or thyroxine for deficient patients is critical, we tend not to initiate sex hormone replacement within the early years of treatment, because gonadal function eventually returns for many of these patients. In a series of 50 patients with giant prolactinomas, 87% had hypogonadotropic hypogonadism at diagnosis, with 32% recovering gonadal function after cabergoline treatment [2] . The series also reported initial incidence of central hypothyroidism (55%), GH deficiency (28%), and hypocortisolism (7%), however, rates of recovery were not noted. In comparing pituitary dysfunction in men presenting with giant prolactinomas (n = 26) versus smaller macroprolactinomas (n = 55), Tirosh et al. [3] observed central hypothyroidism and/or hypocortisolism with 42.9% of giant prolactinomas compared to 17.9% of smaller macroadenomas; these deficiencies persisted post-cabergoline in 34.8% versus 9.1% of patients respectively.
Because dopamine agonist therapy is usually lifelong for patients with macroadenomas, we suggest that hormonal replacement should be withdrawn periodically to assess for recovery of pituitary function.
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